A growing understanding of the intricacies of thyroid health, hormonal imbalances and therapies, as well as advancements in other facets of the burgeoning field of clinical endocrinology have drawn increased attention to novel treatment modalities and their potential to relieve –and even prevent – many symptoms of the aging process. To optimize treatment strategies and patient health outcomes, it is increasingly important for clinicians to stay up-to-date on the latest developments in hormone health. At one of our most popular events, the Bioidentical Hormone Replacement Therapy Symposium, a panel of experts will review the most recent and relevant research available, analyze the medical evidence surrounding hormone therapies, and delve into strategies for safely and effectively merging them into clinical practice. From thyroid optimization to growth hormone deficiency, attendees will have the opportunity to explore the most clinically current topics in the field through a series of expert-led sessions curated to provide a comprehensive overview of the latest updates in endocrinology.
While there is no magic bullet or cure to effectively reverse or stall the aging process, many experts believe that bioidentical hormone replacement therapy (BHRT) comes close. BHRT technically refers to the use of hormones that mimic the endogenous hormones produced by our bodies, with the ability to restore normal physiological pathways with optimal bodily responses. Because aging results in a myriad of declining health issues, BHRT has the potential to restore declining hormone levels, while slowing the aging process, preventing chronic disease, and restoring vigor and vitality.
Kenneth Orbeck, DO practices bioidentical hormone therapy at his integrative and functional medicine practice in South Carolina, citing that hormonal therapy is in large part effective because it requires doctors to have routine contact with patients. This, in turn, delivers optimal results, as patients are not simply receiving prescriptions, but rather being continuously monitored by physicians. “I have no rejections, no infections…it does take training, and you have to understand the therapy, but this ensures a very consistent, linear delivery.” Dr. Orbeck’s patients have been treated for a range of symptoms often associated with aging, including hot flashes, night sweats, decreased libido, fatigue, and irritability.
Jennifer Landa, MD, Chief Medical Officer of BodyLogicMD, has likewise dedicated her practice to bioidentical hormone therapy and preventive medicine, in order to assist men and women resolve menopausal and andropausal symptoms. Dr. Landa explains that results are often contingent upon the ways in which hormones are administered, in addition to the fact that not all hormones are created equally. “Only someone trained as an expert knows the good and bad, and really understands the studies. When we talk bioidentical, it is a way of saying the same exact chemical structure of what is in our body naturally. People do not realize that there are already plenty of prescriptions with bioidentical hormones.” Like Orbeck, Landa’s patients have continuously experienced positive health and wellness through hormonal balance and preventive medicine, in large part to customized BHRT therapy.
Landa clarifies that much of the hormone literature is inaccurate, because most of the studies are conducted with ‘bad’ hormones, like progestin. Landa further discusses a study at Yale, in which researchers and scientists stated that the women only taking estrogen should have stayed on it, and that many more women died of heart disease because they were taken off of their hormones. Landa states, “Timing is of the essence in hormone therapy. Unfortunately, many doctors are still not schooled properly in this area. Even the American College of OBGYN has agreed that we should not be taking older women off of hormones, as symptoms will likely recur.”
Sahar Swidan, PharmD, President & CEO of Pharmacy Solutions in Ann Arbor, Michigan—a uniquely personal, educational specialty pharmacy—and Clinical Associate Professor of Pharmacy at the College of Pharmacy at University of Michigan, explains that while we continue to lump bioidentical hormones with synthetic hormones, they are physiologically extremely different—“Yet you cannot pick up a medical article without clumping them together. Estrogens are not all the same.” Swidan describes the process of hormone therapy as highly individualized, and that physicians must understand their patients’ levels before prescribing hormones. “The earlier we start hormone therapy, the better people do. I tell people: I promise you, you don’t have a Prozac deficiency…you probably have a progesterone deficiency.”
Thierry Hertoghe, MD comes from a family that has worked with bioidentical hormone therapy for four successive generations. Like Swidan and Landa, he believes that BHRT represents the most powerful tools in order to stay healthy, and maintain physical appearance. He elucidates that BHRT has the capacity to treat causes, conditions, and not solely consequences; more importantly, Hertoghe firmly believes that BHRT is both safer and more efficient. “It is personalized, and I can vary the doses. In standardized pharmaceutical medicine, you have one or two doses—but you certainly do not have the possibility of 15-20 doses, depending on the patient. BHRT allows us to fine-tune treatment.” Hertoghe further illuminates the ability of hormone therapy to treat several types of disorders: both physical and psychological, that stem from hormonal imbalances.
A4M/MMI will be hosting a BHRT Symposium in Nashville, from September 27-30. During the three-day workshop, experts will analyze the medical evidence surrounding BHRT, while participants can learn from instructors actively practicing this specialty. Lecturers will discuss the ways in which to identify signs of hormonal deficiencies in patients, and how to subsequently treat imbalances. Sessions will ultimately allow attendees to gain the information needed to safely and effectively merge BHRT into practice. Register now.
Previous research on the effects of testosterone therapy on cardiovascular outcomes has yielded inconsistent results. Jacques Baillargeon, from the University of Texas Medical Branch at Galveston (Texas, USA), and colleagues examined enrollment and claims Medicare data 25,420 Medicare beneficiaries 66 years or older treated with testosterone for up to eight years.. Men of the same age, race, Medicaid eligibility, and health status who did not receive testosterone therapy were used as a control group for comparison. The analyses showed that testosterone therapy did not associate with an increased risk of heart attack. Further, testosterone users with a higher probability of cardiovascular problems had a lower rate of heart attacks in comparison to equivalent patients who did not receive testosterone therapy. Observing that: “Older men who were treated with intramuscular testosterone did not appear to have an increased risk of [heart attack],” the study authors submit that: “For men with high [heart attack] risk, testosterone use was modestly protective.”